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Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced
breast cancer
H Gabra, DA Cameron LE Lee, J Mackay and RCF Leonard
ICRF Medical Oncology Unit and Longmore Breast Unit, on behalf of Edinburgh Breast Group, Western General Hospital,
Edinburgh, UK.
Summary Drug scheduling alterations can improve the therapeutic index of both 5-fluorouracil and
anthracyclines. We investigated a regimen of weekly doxorubicin and continuous infusional 5-fluorouracil
(AcF) in loco-regionally recurrent and metastatic breast cancer. The aims of this phase II study were to use
low-dose weekly anthracyclines in a patient group where liver metastases are a frequent problem, to optimise
scheduling of 5-fluorouracil using continuous infusion and to conserve alkylating agent use for late
intensification in responding patients. Fifty-six patients received 5-fluorouracil 200 mg m2 day-' and
doxorubicin 20 -30 mg m-2 week-1 for at least 6 weeks. Sixty-two percent were chemonaive. Patients were
evaluated for dose intensity, response, toxicity and survival. Of the assessable patients, 76% achieved UICC
response criteria (20% complete response, 56% partial response). WHO grade 3+ toxicities were: alopecia,
98%; mucositis, 62%; neutropenia, 22%; and grade 3 palmar-plantar syndrome, 24%. Median survival was
13 months, with visceral metastasis conferring a significantly worse outcome (P=0.03). Grade 3+ mucositis
was more frequent with planned doxorubicin dose intensity >25 mg m 2 week-' (P=0.04). AcF is highly
active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose
therapy.
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With the intention of achieving improved palliation and
improved survival, we have devised a regimen which aims to
produce rapid remission induction with a high response rate
and acceptable toxicity, while at the same time withholding
alkylating agents for use in a high-dose intensification phase
at the time of best conventional response. We chose the
combination of weekly bolus doxorubicin and continuous
infusional 5-fluorouracil (AcF). There has been interest
recently in scheduling alterations of these agents in an
attempt to produce improved response rates and increased
dose AUCs while minimising acute toxicities, i.e. attempting
to enhance the therapeutic index of these agents (Hansen et
al., 1987; Twelves et al., 1991).
Weekly doxorubicin does not appear to compromise
response rates in comparison to a 3 weekly schedule of the
same total dose (Richards et al., 1992). Impaired liver
function sometimes necessitates dose reduction of anthracy-
clines when used at conventionally 'maximum' doses. This
problem can be circumvented by weekly therapy involving a
similar or increased total anthracycline dose intensity but
with lower peak plasma levels (Twelves et al., 1989).
We therefore designed a non-randomised single arm
(phase II) study incorporating doxorubicin dose escalation
to investigate this regimen in patients with aggressive loco-
regional relapse and/or visceral metastatic disease. The
primary end point for our study was response rate after at
least 6 weekly cycles of AcF. We also report here toxicity,
survival and disease progression data.
Patients and methods
Patient population
Approval for this study was obtained from the local medical
ethics committee. Informed consent was obtained before
commencement of treatment. Patients included had to be 60
years of age or less with a microscopically confirmed
diagnosis of breast carcinoma, either loco-regionally recur-
rent or metastatic.
Disease present was required to be bi-dimensionally
measurable. Performance status (ECOG) was required to be
3 or less. All patients had to be off all chemotherapy for at
least 3 weeks (6 weeks in the case of mitomycin-C), have
recovered from the toxic effects of previous chemotherapy
and white cell count (WCC)> 3 x 1091 1-, plate-
lets) 100 x 1091 -'. Pretreatment cardiac ejection fractions
were mandatory and patients were excluded if they had any
past history of cardiac disease or a cardiac ejection fraction
less than 30%.
Treatment regimen
The treatment regimen consisted of continuous infusional 5-
fluorouracil with weekly bolus doxorubicin (AcF). 5-FU at a
constantly infused dose of 200 mg m-2 day-' was given via a
Hickman line using a continuous ambulatory drug delivery
pump (Pharmacia 'CADD' or Medex 'Walkmed'). The
reservoir of 5-FU was renewed weekly. The dose intensity
of doxorubicin was adjusted to achieve optimisation and
unselected cohorts of patients sequentially received intended
doses of 20, 25 and 30 mg m-2 week-' doxorubicin. Due to
the observation that the 30 mg m-2 week-1 intended dose
was difficult to deliver, a final cohort received a lower
intended dose of 25 mg m-2 week-' (see results below).
Patients received AcF weekly as outpatients for 6 weeks and,
if not progressing on therapy, went on to receive 12 weeks of
therapy.
Dose modification
Full blood count was performed weekly. Doxorubicin was
omitted for week if neutrophils were below 1 x 1091 ' or
platelets below 100 x 1091- or if severe (WHO grade III)
mucositis occurred. 5-FU was discontinued for 1 week if
neutrophils fell below 0.5 x 109 1-1, if platelets fell below
50 x I09 1-1, if severe (WHO grade III) mucositis occurred or
if grade III palmar-plantar syndrome developed (Hansen et
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al., 1987). Both drugs were omitted if any grade IV WHO
criteria toxicity occurred. Otherwise, patients received full-
dose therapy on time. If neutrophils fell below 1 x 109 1-',
patients received augmentin one tab tid, fluconazole 50 mg
daily and acyclovir 200 mg qid for 1 week as prophylaxis, in
addition to corsodyl mouthwash.
Assessment of patients
Symptom assessment, physical examination, haematological
and biochemical parameters and clinically indicated radi-
ology were performed 6 weekly to define disease response as
measured by standard UICC criteria (Hayward et al., 1977,
1978). Toxicity was assessed by WHO toxicity criteria
weekly. Patients continued to be seen 6 weekly after
completion of therapy. Selected patients who had an
objective response by UICC criteria (responses confirmed
by two measurements at least four weeks apart) were
considered for high-dose therapy with peripheral blood stem
cell (PBSC) support. Patients routinely discontinued AcF
treatment at 12 weeks if disease progression had occurred or
if they had had 3 consecutive weeks off therapy because of
toxicity.
Statistical methods
Fisher's exact test was used to compare groups for response
and toxicity. Survival of the cohort and its subgroups was
analysed by the Kaplan-Meier/log-rank method.
Results
Patient population
Fifty-six patients with metastatic and locally recurrent breast
cancer were entered over a period of 34 months between
February 1992 and December 1994 (mean age 43.4 years,
range 26-57 years). Fifty-four patients were assessable for
response. One patient had early grade 4 mucositis 3 weeks
into therapy. This patient was included in the dose intensity,
toxicity and survival analysis, but was excluded from the
response analysis. Another patient had essential information
missing and was excluded (Table I).
Of the 56 patients, 45 (80%) had metastatic disease, and
79% of patients had visceral metastases. Eleven patients
(20%) had loco-regional recurrence as their only site of
disease. Sites of metastases are described in Table I. The two
patients with brain metastases (who also had multiple
visceral sites of disease) additionally received whole-brain
palliative radiotherapy. All but one of those with bone
metastases had evaluable disease at other sites. This patient
had a large destructive symptomatic bi-dimensionally
measurable sternal metastasis extending into the adjacent
soft tissue.
Median performance status of all patients was 1 (WHO
criteria) with a range of 0-3. Patients received a median of
11 cycles of AcF (range 3 -19) (see Table I).
Previous therapy
Twenty-one patients (38%) had received previous cytotoxic
chemotherapy. Of those who had had previous chemother-
apy, only 2 patients had had more than one previous course.
Ten patients had received adjuvant cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) chemotherapy, and
four had received other adjuvant regimens. Six had received a
previous course of CMF for relapsed disease, but only five
patients (13%) had previously received an anthracycline. In
contrast, all but one of those previously receiving chemother-
apy had bolus fluorouracil as part of adjuvant or non-
adjuvant treatment.
Intended and delivered chemotherapy doses
All patients were planned to receive continuous 5-FU
200 mg m-2 day-' (dose intensity (DI)= 1400 mg m-2
week-'). The mean actual 5-FU dose delivered was
176 mg m-2 day-' (DI= 1274 mg m-2 week-') (see Table
II). Initially, we were cautious in prescribing doxorubicin; the
first 13 patients including five with impaired liver function
were prescribed 20 mg m-2 weekly (one of these 13 had early
Table I Patient characteristics
No. of Percentage
patients of total
Number of patients 56
Mean age (range) 43.4 (26-57)
Locoregional disease only 11 20
Metastatic disease 45 80
Visceral metastases 44 79
Multiple visceral sites 15 27
Number of metastatic sites involved
0 10 18
1 14 25
2 20 36
3 10 18
4 2 4
Sites of metastasis
Locoregional/nodal 35 62
Hepatic 37 66
Pulmonary 22 36
Bone 30 54
Brain 2 4
Performance status
0 13 23
1 25 45
2 15 27
3 3 5
Median (range) oestrogen 14 (0-149)
receptor (fmolmg-1 protein)
Previous hormonal therapy 30 54
Previous chemotherapy 21 38
No previous systemic therapy 10 18
Table II Comparison of intended and actual given dose intensities for three differing intended
doxorubicin dose intensities for the three patient cohorts
Intended doxorubicin dose intensity
20m-2 (n=13) 25m-2 (n=22) 30m-2 (n=20)
Given DOX DI (mean) 14.9 19.5 20.2
Given DOX DI to PR (mean) 18.5 19.8 25.2
Given 5-FU DI (mean) 190.6 166.9 180.5
Response rate (overall)a 89% 75% 70%
CR ratea 44% 20% 15%
Weeks to PR (median)a 6 6 5
Weeks to best response (median)a 8 12 12
an= 12. Dox, doxorubicin; DI, dose intensity; PR, partial response; CR, complete response.
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severe toxicity and was excluded from the response analysis,
but was included in the dose intensity, toxicity and survival
analysis). Observing adequate tolerance, we escalated to
25 mg m-2 weekly (nine patients) and then to 30 mg m-2
weekly (20 patients). Actual dose delivered, however, was
reduced in the 30 mg m-2 week-' intended dose level (Table
II). Because of the difficulty in delivering 30 mg m-2 week-',
the last 13 patients enrolled at an intended dose of
25 mg m-2 week-'. The 25 mg m-2 week-' intended dose
level cohorts are grouped together in Table II (n=22).
The mean intended dose for the entire patient cohort was
25.6 mg m-2 weekly. The mean delivered doxorubicin dose
intensity resulting from delays or reductions was
18.7 mg m-2 week-'. The mean doxorubicin dose intensity
delivered to first documentation of partial response was
21.6 mg m-2 week-'. The given doxorubicin dose intensities
within the intended dose increment cohorts are shown in
Table II.
Responses
Of 54 assessable patients, 11 (20%) achieved a complete
response (CR) and 30 (56%) achieved a partial response
(PR), giving an overall response (OR) rate of 76% (95%
confidence interval, 62-87%). Four patients had progressive
disease on therapy (Table III).
Of patients with visceral metastases (hepatic, pulmonary
and brain), 14% achieved CR, with an OR of 76% (33/42).
Of patients with hepatic metastases, 16% (6/37) achieved CR
with 76% (28/37) OR. Of these patients, 26 had abnormal
liver function tests (LFTs) and 22/26 responded (85%). Of
those with normal LFTs, 6/11 responded (54%). This
difference was owing to more partial responses in the group
with abnormal LFTs. Three patients in each group (hepatic
metastases with or without abnormal LFTs) had a complete
response.
A median of 6 weeks therapy was required for patients to
achieve PR, and the median time to best response was 11
weeks (range 5- 17 weeks).
The responses noted were typically rapid with 68% of
partial responses seen by 6 weeks and 88% of responses seen
by 7 weeks. In many patients symptomatic and objective
responses were seen by the second week, ahead of any
clinically detectable toxicity.
Table III Response to AcF (n = 54)
Response No. of patients Percentage
Overall 41/54 76a
CR 11/54 20
PR 30/54 56
SD 9/54 17
PD 4/54 7
NA 2/54 4
a95% Confidence interval, 62 -87%. PR, partial response; CR,
complete response; SD, stable disease; PD, progressive disease; NA,
not assessable for response.
The differences seen in response between groups receiving
each intended dose (Table II) or actual given dose increments
of doxorubicin intensity were non-significant by Fisher's
exact test.
Toxicity
As expected, the major toxicities of this regimen were
mucositis, neutropenia, alopecia and the palmar -plantar
syndrome (Table IV). There were 11 episodes (19%) of
Hickman line complications (thrombosis, sepsis, line falling
out) but no treatment-related deaths.
Fisher's exact test was used to compare toxicity for
intended doxorubicin dose intensities at the three levels of
20 mg m-2 week-', 25 mg m-2 week -' and 30 mg m-2
week-'. Those allocated to a planned dose of > 25 mg m-2
week- ' doxorubicin suffered significantly more grade 3 +
mucositis (P= 0.04) compared with those with a planned dose
intensity of 25 mg m-2 week-'.
Progression and survival
Thirty patients within the AcF group went on to receive
PBSC-rescued high-dose therapy. These patients probably
skew the progression-free and survival data. We have
therefore not included Kaplan- Meier survival curves as
they are not representative of the study regimen.
Median follow-up of the group is 18.5 months (range 9-
38 months). Median overall survival of the whole group was
13 months and that of patients with visceral metastases 12
months. Those without evidence of visceral disease at entry
did significantly better (P=0.037). Median time to progres-
sion for the whole group was 10 months. Progression-free
survival for those without visceral metastases was also
significantly longer (P=0.031).
Discussion
Several studies have suggested independent improvements in
the therapeutic index of both 5-FU in breast (Hansen et al.,
1987; Gordon et al., 1990) and colonic (Lokich et al., 1989)
cancer; and of anthracyclines in breast cancer (Gordon et
al., 1990) and non-small-cell lung cancer (Valdivieso et al.,
1984) using frequent low-dose scheduling. Other studies in
breast cancer have shown equal efficacy and toxicity of low
dose weekly anthracyclines compared with the three weekly
regimens but demonstrated worsened quality of life for the
weekly regimen (Twelves et al., 1991; Richards et al., 1992).
The AcF regimen has potential, through alterations of
schedule, to improve the therapeutic indices of both 5-FU
and doxorubicin. The data demonstrate that this regimen
induces rapid remissions with a 20% CR rate, yet retains a
tolerable toxicity profile. The CR rate for visceral metastases
with AcF is similar to the aggressive Duke AFM remission
induction regimen (achieved in 19% of their patients) (Jones
et al., 1990).
Table IV Toxicities experienced with AcF (n = 55)
WHO grade Grade 3 + 4 toxicity
WHO toxicity 0 1 2 3 4 Number %
Alopecia 0 0 1 54 0 54/55 98
Mucositis 3 6 12 33 1 34/55 62
Palmar-plantar syndromea 6 19 17 13 0 13/55 24
Neutropenia 15 16 12 10 2 12/55 22
Nausea/vomiting 45 2 8 0 0 0/55 0
Diarrhoea 51 2 1 1 1 1/55 2
aToxicity scale for palmar-plantar syndrome from Hansen et al., 1987.
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Table V Dose intensity analysis comparing AcF with the standard
doxorubicin/5-FU regimens AFM and CAF
AcF dose intensity relative
to standard regimen (RDI)
AFM CAF
5-FU 1400mgm-2week-' 1.12 7.0
Doxorubicin
20 mg m-2 week-' 0.8 1.2
25mgm-2 week-' 1.0 1.5
30 mg m-2 week-' 1.2 1.8
ARDI
20 mg m-2 week-' 0.64 2.73
25mgm-2week-' 0.71 2.83
30mgm-2 week- 0.77 2.93
ARDI, average relative dose intensity for the whole AcF regimen
relative to the standard regimens. (For AFM see Jones et al., 1990; for
CAF see Smith and Powles, 1991.)
Longer-term adverse effects such as cardiotoxicity may be
reduced by alteration in the scheduling of anthracyclines
(Torti et al., 1983; Valdivieso et al., 1984; Weiss and
Manthel, 1980), and we felt that this was important as the
probability of cyclophosphamide-induced cardiotoxicity is
increased by prior doxorubicin therapy (Gottdiener et al.,
1981). (Cyclophosphamide is used in the PBSC recruitment
phase of our programme.)
The concepts of dose intensity and dose scheduling cannot
currently be unified into one theory for tumour response
(Hryniuk, 1988; Hryniuk and Brush, 1984). It is possible that
there is an improvement in the therapeutic index of this
regimen as a result of scheduling changes of these drugs. This
may be due to increased dose intensity as a result of modified
organ toxicity, but further studies are required to define this.
Dose intensity analysis suggests that the relative dose
intensities of 5-FU and doxorubicin in AcF compare
favourably with other doxorubicin and 5-FU-containing
regimens (Table V).
Toxicities with this regimen are acceptable and the most
troublesome of these, mucositis, was tolerated surprisingly
well with an active prophylactic approach to mouth care.
In the absence of any clinical difference in response
between the 25 and 30 mg m-2 week-' doxorubicin doses
and in view of a relationship between higher doxorubicin
dose intensity and grade 3 mucositis, we have now adopted a
dose of 25 mg m-2 week-' as being optimally tolerable and
effective. Given the small subgroup numbers and the tight
relative dose intensity range, it is not surprising that we failed
to demonstrate a relationship between doxorubicin dose
intensity and any of the outcome or toxicity parameters
(apart from mucositis).
As this regimen was developed specifically for remission
induction before high-dose therapy, some comments about
the timing of the latter are pertinent. If response to
conventional chemotherapy serves as a marker of optimal
selection for intensification, then this is probably after the
seventh cycle when 88% of responding patients should have
achieved a partial response. If, however, maximal debulking
is felt to be important, then the optimal timing of high-dose
therapy lies between the tenth and twelfth cycle.
In our programme patients who achieve CR or definite PR
are considered for the high-dose therapy/PBSC-rescue arm of
the programme. It will therefore be difficult to assess the
contribution of AcF to overall survival of this best-
responding subgroup of patients, and removal of this group
from the cohort would, of course, skew the survival data
towards the poorly responding patients. The survival of
patients with visceral metastases appears to be much better
than expected compared with our own unpublished and
published (Gregory et al., 1993) historical controls (12.5 vs 7
or 4.5 months) and may therefore be related to the high-dose
therapy component of the programme, but longer follow-up
is clearly required for these patients. We believe that use of
this induction regimen allows the majority of patients with
poor-prognosis advanced breast cancer to achieve valuable
palliative responses with tolerable toxicity and impressive
debulking, which are justifiable aims in themselves. In
addition, this regimen permits patients the option of entry
into high-dose therapy studies.
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